Literature DB >> 12379532

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis.

A P Cairns1, M K J Duncan, A E Hinder, A J Taggart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379532      PMCID： PMC1753946          DOI： 10.1136/ard.61.11.1031

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  15 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 3.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

4.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

5.  A randomized, pilot trial of etanercept in dermatomyositis.

Authors: 
Journal:  Ann Neurol       Date:  2011-06-17       Impact factor: 10.422

Review 6.  Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.

Authors:  Iris Navarro-Millán; Sebastian E Sattui; Jeffrey R Curtis
Journal:  Clin Ther       Date:  2013-10-22       Impact factor: 3.393

7.  Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.

Authors:  Daiju Iwata; Kenichi Namba; Kazuomi Mizuuchi; Nobuyoshi Kitaichi; Satoru Kase; Yuko Takemoto; Shigeaki Ohno; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-11       Impact factor: 3.117

8.  Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.

Authors:  Min-Jung Kang; You-Hyun Lee; Jisoo Lee
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

9.  Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.

Authors:  Maurizio Benucci; Gianantonio Saviola; Paola Baiardi; Emanuela Cammelli; Mariangela Manfredi
Journal:  Clin Rheumatol       Date:  2007-10-10       Impact factor: 2.980

10.  Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs.

Authors:  Ditina Desai; Raphaela Goldbach-Mansky; Joshua D Milner; Ronald L Rabin; Keith Hull; Frank Pucino; Nona Colburn
Journal:  Ann Pharmacother       Date:  2009-05       Impact factor: 3.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.